Alpine Immune Sciences, Inc. financial data

Industry
Pharmaceutical Preparations
Location
188 East Blaine St., Suite 200, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
Nivalis Therapeutics, Inc. (to 7/25/2017), N30 Pharmaceuticals, Inc. (to 11/25/2014)
Latest financial report
10-Q - Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 581 % +65.4%
Debt-to-equity 25.7 % -61.9%
Return On Equity -41.8 % +29%
Return On Assets -11.8 % +50.9%
Operating Margin -90.9 % +64.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.6M shares +37.3%
Common Stock, Shares, Outstanding 65.6M shares +37.3%
Entity Public Float 349M USD +164%
Weighted Average Number of Shares Outstanding, Basic 64M shares +34.6%
Weighted Average Number of Shares Outstanding, Diluted 64M shares +34.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 56.5M USD +119%
Research and Development Expense 83.8M USD +14%
General and Administrative Expense 24.1M USD +29.6%
Operating Income (Loss) -51.4M USD +22.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -32.1M USD +42.1%
Income Tax Expense (Benefit) 103K USD
Net Income (Loss) Attributable to Parent -36.8M USD +42%
Earnings Per Share, Basic -0.64 USD/shares +63.6%
Earnings Per Share, Diluted -0.64 USD/shares +63.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33M USD +128%
Accounts Receivable, after Allowance for Credit Loss, Current 42K USD -93.7%
Assets, Current 308M USD +55.1%
Deferred Income Tax Assets, Net 0 USD -100%
Property, Plant and Equipment, Net 1.36M USD -19.7%
Operating Lease, Right-of-Use Asset 7.32M USD -9.12%
Assets 374M USD +42.6%
Accounts Payable, Current 4.17M USD +151%
Accrued Liabilities, Current 16.9M USD +40.4%
Contract with Customer, Liability, Current 10.2M USD -74.7%
Liabilities, Current 32.2M USD -43.5%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 8.71M USD -11.5%
Liabilities 40.9M USD -55.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -263K USD +35.4%
Retained Earnings (Accumulated Deficit) -274M USD -15.5%
Stockholders' Equity Attributable to Parent 333M USD +96.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 182M USD +48.2%
Liabilities and Equity 374M USD +42.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.7M USD -5.88%
Net Cash Provided by (Used in) Financing Activities 19.4M USD
Net Cash Provided by (Used in) Investing Activities -2.56M USD -109%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 65.6M shares +33.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.9M USD -1101%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.3M USD +126%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 63.9M USD +16.5%
Deferred Tax Assets, Gross 65.9M USD +15.4%
Operating Lease, Liability 9.91M USD -8.55%
Depreciation 147K USD +5%
Payments to Acquire Property, Plant, and Equipment 19K USD -79.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.7M USD +41.6%
Lessee, Operating Lease, Liability, to be Paid 13.8M USD -13%
Property, Plant and Equipment, Gross 4.32M USD +8.33%
Operating Lease, Liability, Current 950K USD +20.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.17M USD +2.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.94M USD +2.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 100K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.85M USD -22.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.22M USD +2.63%
Deferred Tax Assets, Operating Loss Carryforwards 23.2M USD +24.8%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.87M USD +33.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.28M USD +2.65%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.96M USD -12.4%
Share-based Payment Arrangement, Expense 12.1M USD +21.8%
Interest Expense 28K USD -92.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%